ReviewFrontiers in endocrinology2026
Dose-response relationships of normal blood lipid levels in metabolic and endocrine diseases: mechanistic similarities, differences, and functional insights.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As major products of lipid metabolism, blood lipids not only participate in the maintenance of energy homeostasis and the formation of cellular structures, but are also closely involved in endocrine signaling regulation. Although hyperlipidemia is a well-recognized pathogenic factor, a systematic understanding of the potential effects of lipid fluctuations within the normal reference range on metabolic and endocrine homeostasis remains lacking. Current epidemiological evidence suggests that the relationship between blood lipid levels and health risk does not follow a single all-or-none threshold pattern. Even within the clinically defined normal range, variations in certain lipid components may still show dose-response relationships with disease risk, and this continuous effect appears to be complex and heterogeneous across different metabolic and endocrine disorders. This review aims to systematically summarize the available evidence regarding the associations between different lipid components within the normal range and the risk of major metabolic and endocrine diseases. Particular emphasis is placed on comparing the similarities and differences in dose-response relationships across disease spectra and on exploring their potential shared and disease-specific mechanisms, including lipotoxicity-mediated β-cell dysfunction, the early initiation of insulin resistance, and abnormalities in feedback regulation along endocrine axes. Overall, traditional static lipid reference values may not always adequately reflect an individual's true metabolic risk. Future research should move beyond the conventional concept of achieving lipid targets and shift toward more refined risk assessment based on dose-response relationships, with the aim of clarifying the risk gradients of different lipid components within the normal lipid range and the contexts in which they apply. Such efforts may provide a basis for the early identification of metabolic and endocrine diseases, lifestyle intervention, and individualized risk management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.